New Research Emerges on Innovative Standardized Bean Extract

indenaPhaseolus vulgaris_1web.jpg

10 Mar 2014 --- In line with its tradition of a research-based company, Indena has carried out further studies on its products for the health food market and is pleased to bring at Vitafoods 2014 its latest innovative standardized bean extract of Phaseolus vulgaris L. - Beanblock. According to the most recent clinical results it shows high performance for the regulation of appetite and healthy blood sugar levels.

Control of body weight represents today one of the most relevant target in the management of the epidemic problem of overweight and consequently with all the health risks connected with this condition, particularly when associated with hypertension and glucose intolerance. A balanced program of dietary intervention coupled with physical activity still represents a major tool in weight control. This apparently simple and reasonable approach is by far limited in efficacy by several reasons connected with the extremely complicated metabolic network resulting in weight control.

The possibility to control dietary carbohydrates metabolism and absorption seems a very promising approach. This has been partially achieved in recent years by using the so-called starch-blockers mostly connected with the inhibition of α-amylase, the most important enzyme involved in the gastrointestinal degradation of starch.

Starting from these concerns Indena has developed Beanblock, looking at the possibility to add new values to products provided with the capacity to modulate carbohydrate metabolism and absorption.

Beanblock is a patented purified bean (Phaseolus vulgaris L.) extract obtained from a single and specific Italian bean variety (Lamon) particularly rich in α-amylase inhibitor. It is triple standardized: enzymatically - inhibiting activity U/mg:≥1.100); chemically - ≥6% (HPLC -% w/w) in α-amylase inhibitor protein complex; biologically – haemagglutinating activity ≥ 10.000 ≤ 30.000 (HAU/g). Beanblock is standardized to contain a very high amount of α-amylase inhibitor (more than 100-fold in respect of the main available products on the market) together with the proper amount of bean PHA.

Beanblock is supported and proven effective by extensive preclinical data. Moreover, acute oral administration in healthy volunteers has shown that when employed as a supplement in a mixed Mediterranean balanced meal Banblock positively affects glucose metabolism; it also modulates ghrelin secretion and induces a longer duration of satiety, thus suggesting a potential use to control excessive food intake.

To know more, feel free to contact us, meet us at our booth no 17041 at Vitafoods International in Geneva and attend the seminar presentation ”Beanblock: a double-standardized bean extract for post-prandial blood glucose and appetite control” on Tuesday, May 6th, 15:45 – 16:15 – Seminar Theatre.
1. Fantini et al., J. Agric. Food Chem. 57:9316-9323 (2009)
2. Carai et al., Diabetes Metab. Syn. Obes. Targ. Ther. 2:145-153 (2009)
3. Maccioni et al., Br. J. Nutr. 104:624-628 (2010)
4. Loi, B., et al., Fitoterapia 85:14-9 (2013)
5. Carai M. A., et al., Br. J. Nutr. 106; 762; (2011)
6. Spadafranca A., et al., Br. J. Nutr. 109(10):1789-95 (2013)

To contact our editorial team please email us at

Indena S.p.A.


Indena is the world's leading company in the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and personal care industries.

Indena, a privately owned Italian company, has around 800 employees (10% of them dedicated to full-time research)  and has cultivation, manufacturing, and sales in more than 70 countries throughout the world.

The key to Indena's success is its research, covering: the screening of medicinal plants for pharmacological benefits; the identification of new active principles; the development of cutting-edge extraction and purification systems for industrial applications.

Phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestige universities and private research institutes in the biological assessment of the safety and effectiveness of its products up to clinical phase I/II.

A key strategic research objective is the development of new active principles for pharmaceutical applications. This also forms an indispensable base for the health-food and personal care industries.

The pharmaceutical side of the company is focused mainly on anti-cancer drugs, which are produced to US-FDA, ICH and EU standards at Indena's High Containment Manufacturing facilities in Settala, Italy. Indena's drug discovery strategy is to develop new chemical entities up to "Phase I/II" of clinical studies, and then license them to pharmaceutical companies.

Today Indena is also concentrating its efforts on the industrial production of high-quality standardised botanical derivatives, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and prevent damage caused by free radicals.

Backed by more than 90 years of botanical experience, Indena has developed a plantation network, managed by experts, to supply its research and production centres with officinal plants, while ensuring bio-diversity and protecting the ecosystem from uncontrolled harvesting. Today more than 60% of the raw material used in manufacturing comes from cultivations.

Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations. There is constant communication and interaction between the company's experts, who cooperate on the updating of all the main pharmacopoeias, and the major international regulatory authorities such as WHO, EMA, and ESCOP.
The company has more than 150 primary patents and has published more than 700 scientific studies.

Related Articles

Health & Nutrition News

Weekly Roundup: Aker BioMarine enters partnership to boost sustainable krill harvests, Nestlé Cereals joins PHE campaign

11 Jan 2019 --- In nutrition news this week, Aker BioMarine and Cognite are to digitalize the krill company's harvesting and manufacturing operations to improve its sustainability efforts. It comes as Antarctic krill company Rimfrost gains its second license for krill harvesting in Antarctica. A number of Nestlé cereals are to bear the “Good Choice” badge from the recently launched Change4Life campaign from Public Health England (PHE). In research updates, Sabinsa’s probiotic LactoSpore has illustrated functional benefits such as survival during simulated digestion. Quercefit, Indena’s Phytosome formulation of quercetin has demonstrated strong results in terms of bioavailability, efficacy and high tolerability in a recent study.

Health & Nutrition News

Drug-nutrient interaction: Scientific backing is key to quelling concerns

17 Oct 2018 --- Growing consumer and industry awareness of potential drug-nutrient interactions is creating both challenges and opportunities for dietary ingredients companies. With chronic diseases on the rise and consumers keen to boost their diets with supplementation, suppliers have the opportunity to take a key position in providing the right scientific backing and information.

Health & Nutrition News

Botanical boosters: Consumer curiosity and quality control key to category growth

10 Sep 2018 --- Consumers are increasingly clued up on matters of health and nutrition, leading them to seek energy boosters from a wider range of sources than the typical office coffee machine. “What better than plants to deliver the benefits from nature?” asks Maider Gutierrez, Director of Marketing and Sales at Frutarom. “Everything revolves around being natural and that is where botanicals score high.” However, the botanical market has undergone vast changes in recent years, with an increased focus on authenticity and adulteration. How are major players in the industry adapting to these demands?

Health & Nutrition News

Premixes: Strong potential for plant-based nutritionals and protein innovation

07 Aug 2018 --- The aging of the population, increasing scientific evidence of the benefits of nutritional supplementation and the trend toward foods and beverages rather than pills and capsules have led to increased consumer interest in the incorporation of nutrient premixes to support a healthy diet. “Consumers are doing everything they can to stay healthy so that they can stay out of the traditional healthcare system,” says Sam Wright IV, CEO at The Wright Group, which develops custom nutrient premixes, the enrichment of rice and grains, as well as the microencapsulation of vitamins, minerals and omega 3.

Health & Nutrition News

Immunity ingredients space: From Ayurvedic roots to ocean garden

02 Jul 2018 --- The immunity ingredient space is reaching beyond classical vitamins, such as vitamin C, for immune health, with manufacturers highlighting a range of ingredients for their immune boosting properties. From Ayurvedic roots, botanicals, ocean garden's seaweed and yeast beta glucans, the market continues to diversify and expand to keep a growing market engaged. As John Quilter, Vice President and General Manager, GanedenBC & Wellmune, tells NutritionInsight, “Research shows that improving immune function is a leading health concern among consumers globally, with 87 percent expressing an interest in buying food and beverage products that deliver this benefit.”

More Articles